Healthy Skepticism Library item: 13749

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

de la Fuente Cid R, Varela Román A.
[Which is the role of the angiotensin II receptor blockers (ARBs) for the treatment of heart failure? Do we work based on evidence/recommendations or pharmaceutical industry pressure?].
An Med Interna 2007 Dec; 24:(12):607-9
http://www.ncbi.nlm.nih.gov/pubmed/18279002

Abstract:

Chronic heart failure (CHF) represents the first cause of hospitalization in persons older than 6o years in our environment. Beside its incidence and prevalence is increasing although new therapeutic treatments. We think the recommendations of the guidelines of clinical practise are an important instrument to make decisions, although sometimes it is used a numeric language little clear. We do not have either to forget that sometimes patients selected for the clinical trials aren t really representative. Finally to add that pharmaceutical industry spends a lot of money on investigating active basics, but as company itself is needs to obtain benefits. With all of this, in this article we try to study the role of angiotensin II receptor blockers (ARBs) occupy in the medic strategy for the planification of a patient s treatment with chronic heart failure.

ramondfc@yahoo.es

Keywords:
Publication Types: English Abstract MeSH Terms: Angiotensin II Type 1 Receptor Blockers/therapeutic use* Drug Industry Evidence-Based Medicine Heart Failure/drug therapy* Humans Practice Guidelines as Topic Substances: Angiotensin II Type 1 Receptor Blockers

Notes:

[Article in Spanish]